Rep. Mike Castle is planning on polling a potential three-way Senate race to test his chances as a write-in candidate, a Delaware Republican tells POLITICO. Castle, who lost his GOP primary by a ...

TissueCypher is Castle’s precision medicine risk-stratification test that predicts a patient’s individual risk of progression from Barrett’s esophagus (BE) to esophageal cancer FRIENDSWOOD, Texas, ...

Castle Biosciences will present TissueCypher Barrett’s Esophagus test data at DDW 2025, emphasizing risk stratification and personalized patient management. Castle Biosciences, Inc. will present new ...

Castle Biosciences has received assay approval from the New York State Department of Health (NYSDOH) in the US for its TissueCypher Barrett’s oesophagus (BO) test. The Texas-based diagnostics company ...

This marks the fourth consecutive year that Castle has earned a MedTech Breakthrough Award for its innovative testing solutions FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: ...

Castle Biosciences’ TissueCypher® test can offer patients with Barrett’s esophagus a clearer picture of their risk of developing esophageal cancer. Esophageal cancer is a killer. It’s the eighth most ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today provided an update on its test ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new discovery data from an ...

Castle Biosciences has enrolled over 1,100 patients in a validation study spanning 39 clinical sites as of September 30, 2024. The company, which has demonstrated remarkable revenue growth of 62.43% ...

Castle Rock on Wednesday evening will test a lighting scheme on its eponymous rock monument as part of an effort to determine whether the outcropping should be illuminated year round. Between 9 p.m.